Rayner has acquired the United States distribution rights to Anikavisc, an ophthalmic viscosurgical device (OVD), from Visco Technologies Inc. Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain anterior chamber depth, and enable controlled surgical manipulation, the company said in a press release.

According to Rayner, the acquisition comes on the heels of the US launch of its FDA-approved Sophi phaco platform and as the company continues to expand access to its portfolio, including the RayOne EMV Toric IOL. With the premarket application submission for the RayOne Galaxy AI-designed spiral IOL now complete, Rayner said it is positioning itself to offer a comprehensive, bundle-ready portfolio in 2026 which will span premium and monofocal IOLs, OVD, and advanced phaco technology.

“We’re excited about what this acquisition means for our US customers,” said Scott Corning, vice president Americas at Rayner. “Anikavisc customers will see no changes to their current arrangements, but its reach and support will grow through our direct sales team from today. This also allows us to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing, and delivers even greater value through one dedicated partner committed to innovation in cataract surgery.”